AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
serdexmethylphenidate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 5448 | 1996626-30-2 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Serdexmethylphenidate is a prodrug of dexmethylphenidate (d-MPH). The mode of therapeutic action in ADHD is not known. Serdexmethylphenidate is not deemed to have pharmacological activity until converted to d-MPH. Dexmethylphenidate HCl is a central nervous system (CNS) stimulant that blocks the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,MAP3K7,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PRKDC,TEK | 22 | |||
| kinase-selectivity-class | AXL,GRK2,TEK | 3 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| March 2, 2021 | FDA | COMMCAVE THERAPEUTICS SA |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N06BA15 | NERVOUS SYSTEM PSYCHOANALEPTICS PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS Centrally acting sympathomimetics |
| MeSH PA | D000697 | Central Nervous System Stimulants |
| MeSH PA | D002491 | Central Nervous System Agents |
Related Drugs by ATC class:
N06BA Centrally acting sympathomimetics 14 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Attention deficit hyperactivity disorder | indication | 406506008 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| EQ 10.4MG BASE;EQ 52.3MG BASE | AZSTARYS | COMMAVE SUB | N212994 | May 7, 2021 | RX | CAPSULE | ORAL | 10858341 | Dec. 9, 2037 | TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) WITH SERDEXMETHYLPHENIDATE AND DEXMETHYLPHENIDATE |
| EQ 10.4MG BASE;EQ 52.3MG BASE | AZSTARYS | COMMAVE SUB | N212994 | May 7, 2021 | RX | CAPSULE | ORAL | 10954213 | Dec. 9, 2037 | TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) WITH SERDEXMETHYLPHENIDATE AND DEXMETHYLPHENIDATE |
| EQ 5.2MG BASE;EQ 26.1MG BASE | AZSTARYS | COMMAVE SUB | N212994 | May 7, 2021 | RX | CAPSULE | ORAL | 10858341 | Dec. 9, 2037 | TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) WITH SERDEXMETHYLPHENIDATE AND DEXMETHYLPHENIDATE |
| EQ 5.2MG BASE;EQ 26.1MG BASE | AZSTARYS | COMMAVE SUB | N212994 | May 7, 2021 | RX | CAPSULE | ORAL | 10954213 | Dec. 9, 2037 | TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) WITH SERDEXMETHYLPHENIDATE AND DEXMETHYLPHENIDATE |
| EQ 7.8MG BASE;EQ 39.2MG BASE | AZSTARYS | COMMAVE SUB | N212994 | May 7, 2021 | RX | CAPSULE | ORAL | 10858341 | Dec. 9, 2037 | TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) WITH SERDEXMETHYLPHENIDATE AND DEXMETHYLPHENIDATE |
| EQ 7.8MG BASE;EQ 39.2MG BASE | AZSTARYS | COMMAVE SUB | N212994 | May 7, 2021 | RX | CAPSULE | ORAL | 10954213 | Dec. 9, 2037 | TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) WITH SERDEXMETHYLPHENIDATE AND DEXMETHYLPHENIDATE |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| EQ 10.4MG BASE;EQ 52.3MG BASE | AZSTARYS | COMMAVE SUB | N212994 | May 7, 2021 | RX | CAPSULE | ORAL | May 7, 2026 | NEW CHEMICAL ENTITY |
| EQ 5.2MG BASE;EQ 26.1MG BASE | AZSTARYS | COMMAVE SUB | N212994 | May 7, 2021 | RX | CAPSULE | ORAL | May 7, 2026 | NEW CHEMICAL ENTITY |
| EQ 7.8MG BASE;EQ 39.2MG BASE | AZSTARYS | COMMAVE SUB | N212994 | May 7, 2021 | RX | CAPSULE | ORAL | May 7, 2026 | NEW CHEMICAL ENTITY |
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| D11401 | KEGG_DRUG |
| 0H8KZ470DW | UNII |
| C5237972 | UMLSCUI |
| CHEBI:757632 | CHEBI |
| CHEMBL4301162 | ChEMBL_ID |
| 134823895 | PUBCHEM_CID |
| DB16629 | DRUGBANK_ID |
| CHEMBL4298139 | ChEMBL_ID |
| 10916 | INN_ID |
| C000718174 | MESH_SUPPLEMENTAL_RECORD_UI |
| 11450 | IUPHAR_LIGAND_ID |
| 1179218001 | SNOMEDCT_US |
| 1179219009 | SNOMEDCT_US |
| 4040657 | VANDF |
| 344090 | MMSL |
| 39359 | MMSL |
| d09719 | MMSL |
| 018662 | NDDF |
| 018663 | NDDF |
| 1996626-29-9 | SECONDARY_CAS_RN |
| 2562176 | RXNORM |
| 0H8KZ470DW | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| AZSTARYS | HUMAN PRESCRIPTION DRUG LABEL | 2 | 65038-286 | CAPSULE | 26.10 mg | ORAL | NDA | 32 sections |
| AZSTARYS | HUMAN PRESCRIPTION DRUG LABEL | 2 | 65038-286 | CAPSULE | 26.10 mg | ORAL | NDA | 32 sections |
| AZSTARYS | HUMAN PRESCRIPTION DRUG LABEL | 2 | 65038-429 | CAPSULE | 39.20 mg | ORAL | NDA | 32 sections |
| AZSTARYS | HUMAN PRESCRIPTION DRUG LABEL | 2 | 65038-429 | CAPSULE | 39.20 mg | ORAL | NDA | 32 sections |
| AZSTARYS | HUMAN PRESCRIPTION DRUG LABEL | 2 | 65038-561 | CAPSULE | 52.30 mg | ORAL | NDA | 32 sections |
| AZSTARYS | HUMAN PRESCRIPTION DRUG LABEL | 2 | 65038-561 | CAPSULE | 52.30 mg | ORAL | NDA | 32 sections |